Genital warts and cost of care in England
- PMID: 21813567
- PMCID: PMC3253068
- DOI: 10.1136/sti.2010.048421
Genital warts and cost of care in England
Abstract
Objectives: To estimate the total number of cases of, and cost of care for, genital warts (GWs) in England, to inform economic evaluations of human papillomavirus vaccination.
Methods: The number of GW cases seen in general practices (GPs) and in genitourinary medicine (GUM) clinics was estimated using the General Practice Research Database and the GUM Clinic Activity Dataset. The overlap in care of cases in the two settings was estimated. The calculated costs of care in GP and hospitals were added to the costs of care in GUM clinics (estimated elsewhere) to estimate the cost of care for GWs in England.
Results: In England, in 2008, GP and GUM saw 80,531 new (157/100,000 population) and 68,259 recurrent (133/100,000 population) episodes, giving a total of 148,790 episodes of care of GWs (289/100,000 population). Seventy-three per cent of cases were seen only in GUM clinics, 22% were seen by a GP before being referred to GUM, and 5% by GPs only. Hospital care was given in 1.3% of cases and contributed 8% of the costs. The average cost of care per episode was £113, and the estimated annual cost of care in England was £16.8 million.
Conclusions: This study provides a fairly comprehensive measure of GW frequency and care in England. GWs exert a considerable impact on health services, a large proportion of which could be prevented through immunisation using the quadrivalent human papillomavirus vaccine.
Conflict of interest statement
Figures


Similar articles
-
The impact of genital warts: loss of quality of life and cost of treatment in eight sexual health clinics in the UK.Sex Transm Infect. 2011 Oct;87(6):458-63. doi: 10.1136/sextrans-2011-050073. Epub 2011 Jun 2. Sex Transm Infect. 2011. PMID: 21636616 Free PMC article.
-
Declining genital Warts in young women in england associated with HPV 16/18 vaccination: an ecological study.J Infect Dis. 2013 Nov 1;208(9):1397-403. doi: 10.1093/infdis/jit361. J Infect Dis. 2013. PMID: 24092908 Free PMC article.
-
Determining the cost of genital warts: a study from Ireland.Sex Transm Infect. 2009 Sep;85(5):402-3. doi: 10.1136/sti.2008.033837. Epub 2008 Nov 12. Sex Transm Infect. 2009. PMID: 19004863
-
Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates.Sex Transm Infect. 2019 Feb;95(1):28-35. doi: 10.1136/sextrans-2018-053606. Epub 2018 Sep 21. Sex Transm Infect. 2019. PMID: 30674687
-
The new human papillomavirus (HPV) vaccine: pros and cons for pediatric and adolescent health.Pediatr Nurs. 2008 Sep-Oct;34(5):429-31. Pediatr Nurs. 2008. PMID: 19051848 Review.
Cited by
-
CO(2) Laser therapy versus cryotherapy in treatment of genital warts; a Randomized Controlled Trial (RCT).Iran J Microbiol. 2012 Dec;4(4):187-90. Iran J Microbiol. 2012. PMID: 23205250 Free PMC article.
-
Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review.BMC Cancer. 2012 Jan 20;12:30. doi: 10.1186/1471-2407-12-30. BMC Cancer. 2012. PMID: 22260541 Free PMC article. Review.
-
Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT.Health Technol Assess. 2020 Sep;24(47):1-86. doi: 10.3310/hta24470. Health Technol Assess. 2020. PMID: 32975189 Free PMC article. Clinical Trial.
-
The impact of genital warts: loss of quality of life and cost of treatment in eight sexual health clinics in the UK.Sex Transm Infect. 2011 Oct;87(6):458-63. doi: 10.1136/sextrans-2011-050073. Epub 2011 Jun 2. Sex Transm Infect. 2011. PMID: 21636616 Free PMC article.
-
Prevalence and incidence of external genital warts in a sample of Italian general female population.BMC Infect Dis. 2017 Feb 6;17(1):126. doi: 10.1186/s12879-017-2202-6. BMC Infect Dis. 2017. PMID: 28166736 Free PMC article.
References
-
- Health Protection Agency STI Annual Data Tables. 2009. http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1203348026613 (accessed 25 Aug 2010).
-
- British Association for Sexual Health and HIV United Kingdom National Guideline on the Management of Ano-genital Warts. 2007. http://www.bashh.org/documents/86/86.pdf (accessed 24 Aug 2010).
-
- De Carvalho N, Teixeira J, Roteli-Martins CM, et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010;28:6247–55 - PubMed
-
- The FUTURE II Group Effect of prophylactic human papillomavirus L1 virus-like particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007;369:1861–8 - PubMed
-
- Dillner J, Kjaer SK, Wheeler CM, et al. ; The FUTURE I/II Study Group Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010;341:c3493. - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical